Danaher Corporation (DHR)

Total return at 5 years: -12.4%/year = -13.7% appreciation + 1.2% dividend. The target price ($106) is ex-dividend; the $10 in dividends collected over 5 years are added separately.

By both methods, the value today (DCF $144 · Multiples $94) is below the market price ($221).

Today — expensive, no margin of safety: at $221 trades ~136.2% above its value discounted to today (~$94); the expected return does not even reach the risk-free rate (4.5%).

At 5 years — Sobrevalorado: the expected total return is negative — the price already discounts a demanding scenario that, if not met, results in a loss.

The bridge: the return at 5 years falls below the risk-free rate (4.5%) — which is why there is not even a discount to today's value. To require a 15% annual return, it would need to be bought at ~$59.

Educational / informational. Does not constitute investment advice.

The inverse approach: instead of projecting growth to obtain the value, the market price ($221) is taken as given and it solves for what annual owner-earnings growth would need to hold for 5 years for the present value —at the method's rate (4.5%, no-growth terminal)— to equal that price. It is the disconfirmation test: the expectations the price already pays for, contrasted against the method's projection.

The price discounts growth (14.1%/year) above our base case (5.5%/year) → it is priced for a demanding scenario and leaves little cushion against a slowdown.

That growth implies ~$8.4 bn of owner earnings in year 5 (vs ~$5.7 bn of our base case). It recalculates if the DCF assumptions are edited.

Year-by-year projection of the selected scenario. From each year, two versions of the flow are derived: growth FCF (operating flow − total capex, the cash surplus) and maintenance FCF (the owner earnings: what the business yields if it only sustains its capacity). The flow is returned almost in full (dividend + buyback) or redeployed into the operation, so that EV stays roughly flat and multiples compress because the metric grows, not because of cash accumulation. The valuation is done on EV/NOPAT (dispositivos médicos y diagnóstico). In edit mode, revenue, margins, capex, and exit multiples can be adjusted.

Year 0 = TTM at 26-Jun-2026 (revenue $25.107bn, operating margin 20.4%). It is valued on EV/NOPAT rather than P/E because the non-GAAP reconciliation of adjusted earnings per share that Danaher usually publishes separately was not located in the 10-K sections reviewed; the same criterion as Boston Scientific (BSX) in this library. The year-1 starting point (~3.2%) is anchored to the average of the recent trajectory (FY24 −0.1%, FY25 +2.9%, TTM +4.6%; FY23 −10.3% excluded as an artifact of the Veralto separation), without crediting the bioprocessing recovery in advance (segment-weighted organic growth in 2025 was only ~2.1%: Biotechnology +6.5%, Life Sciences −1.5%, Diagnostics +1.5%). The operating margin (20.4% TTM, depressed ~130 basis points by 2025 brand/technology/facility impairments) normalizes gradually toward ~21% by year 5. The exit multiple sits at the low-to-mid end of the medical band [16,22]× (17× base) because weak organic growth and the acknowledged slowdown in the pace of acquisitions do not support a higher position; unlike a direct P/E, the EV→equity bridge subtracts real total debt, explicitly charging for the company's leverage. Historical net buybacks (~2.5-3%/year in 2024-2025) are modeled via sharesPath at a more moderate sustainable pace (~1.5%/year) rather than extrapolating the 2024 peak. `reinvestsExcess` is flagged because Danaher is a serial acquirer whose retained cash is redeployed into M&A (even at the declared decelerating pace), it is not accumulated as idle cash.

Today's elevated multiple is the price of growth: if the business grows, the entry point cheapens on its own going forward (the metric grows while EV stays roughly flat). The exit multiple at 3 years is higher than the terminal at 5 years —at 3 years there is more growth still ahead—, so the value curve shows whether value creation is concentrated in the early or the later years. The required return is applied to the base scenario.

They are valued separately, with their own rationale, and are not incorporated into the base or the verdict (they are excess return). When assigning them value — in Editmode —, the total with optionalities updates live, without moving the base.

The verdict, the base CAGR, and the margin of safety are always calculated on the base; optionalities do not alter them (with optionalities at $0 they do not move).

Each card fixes a required annual return and answers: if the business is worth $106 in 5 years, what is the maximum that can be paid today to obtain that return? Since it now trades at $221, the margin of safety is how much cheaper the market is than that maximum. The three thresholds: 4% covers inflation (the floor), 10% is the long-term average return, and 15% is the level of a great investment.

With a target price of $106 in 5 years plus $10 of dividends collected (the dividend adds to the return, not to the price) and a required return of 4.5% annually, the maximum to pay today is $94. Against the current market price ($221), the margin of safety is -136.2% (trades above the maximum → a premium is paid) and the total return at that price would be -12.4% annually.

• Current multiple. Trading at 41× on NOPAT, at the high end relative to the medical-devices-and-diagnostics archetype.
• Estimated 5-year return. -12% versus the current price under the base case.
• Margin of safety. No margin of safety: the price already discounts a demanding scenario.

Each margin over sales, year by year: historical (solid line) → projection (dotted).

• ✕ ROIC exceeds the cost of capital (~10%)
• ✓ CFROIC backs up the ROIC (126%, cash vs. accruals)
• ✕ Healthy balance sheet (low corporate debt)
• ✓ Durable competitive moat (multiple advantages)

• Return on invested capital. ~5.8% on invested capital of ~$74.8 billion that carries the goodwill from decades of acquisitions.
• Operating cash generation. TTM operating cash flow of ~$6.4 billion, though pressured in 2025 by higher working-capital use.
• Effective tax rate. 15.0% in 2025, with guidance of ~17% for 2026.

Annual levels from the official filing (10-K); the % over each bar is the year-over-year (YoY) growth vs the prior year.

Revenue levels by reportable segment (Biotechnology, Life Sciences, Diagnostics) taken directly from the segment note in the 10-K FY2025, as levels rather than rates; the year-over-year growth shown by the component is computed from these levels. The three segments sum to the consolidated FY2025 revenue of $24,568 million.

The % are the annual (year-over-year) growth: each year —historical and projected— vs the prior one; the TTM (trailing 12m) vs the TTM of a year ago, to avoid overlapping windows. The historicals are exact figures from the official filings; the projected years come from the year-by-year model (the intermediate years without their own series are interpolated between the anchors). The projected columns (+1y…+5y) are 12-month windows counted from the TTM close (26-jun-2026): the projection starts from the most recently reported data, not the fiscal year. The projected base is realistic and unbiased — the risk discount is applied at the end, via the required return. The rationale for each metric is in the (i).

• Biotechnology recovering. Organic growth of 6.5% in 2025, a sign of normalization after the bioprocessing air pocket.
• Life Sciences hit. Organic decline of 1.5% in 2025, with a $432 million brand impairment that compressed the segment's margin.
• Diagnostics under pricing pressure. Organic growth of just 1.5%, with prices falling 1.0% due to volume-based procurement programs in China.

• Recurring-revenue model. Consumables, services, and software on an installed base of instruments generate a meaningful recurring-revenue component.
• Regulatory barriers. Most products require FDA clearance, a lengthy process that acts as an entry barrier.
• Weak organic growth. Weighted organic growth in 2025 was just ~2.1%, well below the company's historical pace.
• Geographic diversification. ~59% of sales come from outside the U.S., with ~11% exposure to China.

Not all debt is equal: only the structural needs refinancing; the rest is operational (self-liquidating).

Structural debt is what is exposed to the contraction phase of the cycle; operational debt (leases, matched funding) self-liquidates with the business.

• !Leverage (net debt / EBITDA)Net debt / EBITDA 2.9x
• ✓Interest coverage (EBIT / interest)14.0x
• –Liquidity (current ratio)no data
• ✓Cash quality (CFROIC vs ROIC)CFROIC backs 126% of ROIC
• ✕Value creation (ROIC − 10% bar)-4pp
• ✓Malinvestment test (capex vs incremental ROIC)Capex/D&A 0.5x — no over-investment
• !Float / working capitalConsumes cash $0.3 bn (positive WC)
• ✓Dilution (SBC % of revenue + shares)SBC 1.2% of revenue

A traffic-light interpreted by the method (not generic): float (negative WC) adds up, capex is judged by incremental ROIC (malinvestment test), and a lender is not subjected to corporate solvency. The (i) shows the derivation of each number.

• Leverage. Total debt of ~$26.6 billion versus cash of ~$4.3 billion; moderate leverage for the size of the business, fully charged in the valuation bridge.
• Interest coverage. TTM EBIT of ~$5.1 billion comfortably covers estimated interest expense.
• Liquidity. Cash of ~$4.3 billion and consistent operating cash generation.

Who owns the shares — the alignment and whether there is a controlling shareholder.

• Leadership continuity. Rainer Blair has led the company since 2020, with a stated focus on the Danaher Business System.
• M&A slowdown. The annual report itself acknowledges that the pace of completed acquisitions has declined relative to historical practice.
• Ownership detail. Not available in the annual report sections reviewed; pending the DEF 14A proxy.

• No clear Marks-style discount source is identified (neither forced selling nor missing buyers): the market continues to pay Danaher's historical quality premium despite the organic slowdown.
• Part of the premium may be explained by the expectation that the acquisition engine will reactivate (with the pending Masimo acquisition as the first test), although the annual report itself acknowledges the pace has declined relative to its historical practice.
• The $432 million brand impairment in Life Sciences and the pricing pressure in Diagnostics from China appear to be treated as single-year noise, though that alone does not justify the current multiple.

Absent an identifiable discount source, caution is warranted: the stock may not be cheap under this framework, only appear so on a superficial reading of the business.

The annual return (CAGR at 5 years) in each scenario, with the total period return below — the margin of safety made visual: upside range wide, downside range narrow.

Even in the bear scenario, the return holds at -20%/year (-67% total): the margin of safety protects the downside. The bull (-6%/year, -26% total) exceeds it comfortably — a favorable asymmetry, with a narrow downside range and a wide upside range.

• M&A slowdown. The historical acquisition-driven value-creation engine is stalled according to the annual report itself.
• Pricing pressure in China. Volume-based procurement programs and changes in healthcare reimbursement are pressuring Diagnostics pricing.
• Tax risk from divestitures. If the IRS were to determine that Fortive, Envista, or Veralto did not qualify as tax-free transactions, there would be significant tax liabilities.
• Masimo integration. The pending acquisition absorbs capital and management attention at a time of weak organic growth.

Each thinker's analytical framework applied to our data.

• Buffett / Graham Quality + margin of safety

  Fails the quality gate: wide moat, eroding.

• Peter Lynch Growth at a reasonable price (GARP)

  A stalwart growing 6% at a multiple/growth of 7.5 → expensive for its growth.

• Joel Greenblatt Cheap and high-return (Magic Formula)

  Earnings yield 3% (EBIT/EV) + ROIC 6% → falls outside the Magic Formula.

• Howard Marks Perception vs reality + cycle

  The price discounts 14% vs our 6%: priced for perfection, no favorable mispricing.

• Seth Klarman Capital protection (bear scenario)

  Bear-scenario floor -21%/yr over 5y (material loss) → risk of permanent capital loss.

• Pat Dorsey Moat strength (Five Rules)

  A wide moat, eroding; sources: intangibles, switching costs, efficient scale, cost advantage → partially passes the Five Rules.

• Aswath Damodaran Expectations implied by the price

  The price demands 14% growth, far above our 6% — heroic assumptions.